A revised method for estimating hepatitis B virus transfusion residual risk based on antibody to hepatitis B core antigen incident cases

Transfusion

Volumn 48, Issue 11, 2008, Pages 2308-2314

  Laperche, Syria ^a   Maniez, Michèle ^b   Barlet, Valérie ^b   El Ghouzzi, Marie Hélène ^b   Le Vacon, Françoise ^b   Levayer, Thierry ^b   Lunel, Françoise ^b   Morel, Pascal ^b   Mouillot, Laurence ^b   Piquet, Yves ^b   Pillonel, Josiane ^b  

^a INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; IMMUNOGLOBULIN M; VIRUS DNA;

ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; CONTROLLED STUDY; HEPATITIS B VIRUS; HUMAN; INCIDENCE; RISK FACTOR;

ADULT; ALGORITHMS; BLOOD DONORS; BLOOD TRANSFUSION; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; FRANCE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HUMANS; IMMUNOGLOBULIN M; INCIDENCE; MALE; MODELS, BIOLOGICAL; RETROSPECTIVE STUDIES; RISK; VIREMIA;

EID: 55349103399     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.01873.x     Document Type: Article

References (29)

1. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor study. N Engl J Med 1996 334 : 1685 90.
2. Glynn SA, Kleinman SH, Wright DJ, Busch MP. International application of the incidence rate/window period model. Transfusion 2002 42 : 966 72.
3. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, Pappalardo B, Kleinman SH, for the NHLBI-REDS NAT Study Group. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005 45 : 254 64.
4. O'Brien SF, Yi QL, Fan W, Scalia V, Kleinman SH, Vamvakas EC. Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services. Transfusion 2007 47 : 316 25.
5. Korelitz JJ, Busch MP, Kleinman SH, Williams AE, Gilcher RO, Ownby HE, Schreiber GB. A method for estimating hepatitis B virus incidence rates in volunteer blood donors. National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study. Transfusion 1997 37 : 634 40.
6. Seed CR, Cheng A, Ismay SL, Bolton WV, Kiely P, Cobain TJ, Keller AJ Virology Subcommittee of the National Donor and Product Safety Committee, Australian Red Cross Blood Service. Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT. Transfusion 2002 42 : 1365 72.
7. Kleinman SH, Busch MP. Assessing the impact of HBV NAT on window period reduction and residual risk. J Clin Virol 2006 36 Suppl 1 : S23 9.
8. Hoofnagle JH, Gerety RJ, Barker LF. Hepatitis B core antigen and antibody. Dev Biol Stand 1975 30 : 175 85.
9. Hoofnagle JH, Seef LB, Buskell-Bales Z. Serologic response in HB. Philadelphia (PA) : Franklin Institute Press 1978. p. 219 42.
10. Fleiss J. Statistical methods for rates and proportions. 2nd ed. New York : Wiley Press 1981.
11. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002 42 : 975 9.
12. Van der Bij AK, Coutinho RA, Van der Poel CL. Surveillance of risk profiles among new and repeat blood donors with transfusion-transmissible infections from 1995 through 2003 in the Netherlands. Transfusion 2006 46 : 1729 36.
13. Zou S, Notari EP, Stramer SL, Wahab F, Musavi F, Dodd RY. Patterns of age- and sex-specific prevalence of major blood-borne infections in United States blood donors, 1995 to 2002: American Red Cross blood donor study. Transfusion 2004 44 : 1640 7.
14. Pillonel J, Le Marrec N, Girault A, David D, Laperche S. Epidemiological surveillance of blood donors and residual risk of blood-borne infections in France, 2001 to 2003 Transfus Clin Biol 2005 12 : 239 46.
15. Wang B, Schreiber GB, Glynn SA, Kleinman S, Wright DJ, Murphy EL, Busch MP Retrovirus Epidemiology Donor Study. Does prevalence of transfusion- transmissible viral infection reflect corresponding incidence in United States blood donors? Transfusion 2005 45 : 1089 96.
16. Pillonel J, Barin F, Laperche S, Bernillon P, Le Vu S, Liandier B, Desenclos JC. Human immunodeficiency virus type 1 incidence among blood donors in France, 1992 to 2006: use of an immunoassay to identify recent infections. Transfusion 2008 Epub ahead of print M, Nubling CM, Scheiblauer H, Chudy M, Walch LA, Seifried E, Roth WK, Hourfar MK. Anti-HBc screening of blood donors: a comparison of nine anti-HBc tests. Vox Sang 2006 91 : 237 43.
17. Brojer E, Grabarczyk P, Liszewski G, Mikulska M, Allain JP, Letowska M Polish Blood Transfusion Service Viral Study Group. Characterization of HBV DNA+/HBsAg- blood donors in Poland identified by triplex NAT. Hepatology 2006 44 : 1666 74.
18. Grob P, Jilg W, Bornhak H, Gerken G, Gerlich W, Günther S, Hess G, Hüdig H, Kitchen A, Margolis H, Michel G, Trepo C, Will H, Zanetti A, Mushahwar I. Serological pattern "anti-HBc alone": report on a workshop. J Med Virol 2000 62 : 450 5.
19. Zervou EK, Dalekos GN, Boumba DS, Tsianos EV. Value of anti-HBc screening of blood donors for prevention of HBV infection: results of a 3-year prospective study in Northwestern Greece. Transfusion 2001 41 : 652 8.
20. Yoshikawa A, Gotanda Y, Itabashi M, Minegishi K, Kanemitsu K, Nishioka K Japanese Red Cross NAT Screening Research Group. HBV NAT positive [corrected] blood donors in the early and late stages of HBV infection: analyses of the window period and kinetics of HBV DNA. Vox Sang 2005 88 : 77 86.
21. Alvarez M, Oyonarte S, Rodriguez PM, Hernandez JM. Estimated risk of transfusion-transmitted viral infections in Spain. Transfusion 2002 42 : 994 8.
22. Pillonel J, Laperche S. Trends in risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2003 and impact of nucleic acid testing (NAT). Euro Surveill 2005 10 : 5 8.
23. Gonzalez M, Regine V, Piccinini V, Vulcano F, Giampaolo A, Hassan HJ. Residual risk of transfusion-transmitted human immunodeficiency virus, hepatitis C virus, and hepatitis B virus infections in Italy. Transfusion 2005 45 : 1670 5.
24. Seed CR, Kiely P, Keller AJ. Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus. Intern Med J 2005 35 : 592 8.
25. Gonzalez R, Echevarria JM, Avellon A, Barea L, Castro E. Acute hepatitis B virus window-period blood donations detected by individual-donation nucleic acid testing: a report on the first two cases found and interdicted in Spain. Transfusion 2006 46 : 1138 42.
26. Liu CJ, Chen DS, Chen PJ. Epidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT. J Clin Virol 2006 36 Suppl 1 : S33 44.
27. Zanetti AR, Romano L, Zappa A, Velati C. Changing patterns of hepatitis B infection in Italy and NAT testing for improving the safety of blood supply. J Clin Virol 2006 36 Suppl 1 : S51 5.
28. Comanor L, Holland P. Hepatitis B virus blood screening: unfinished agendas. Vox Sang 2006 91 : 1 12.
29. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007 46 : 160 70.